466 related articles for article (PubMed ID: 12722161)
21. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys.
Lyras L; Zeng BY; McKenzie G; Pearce RK; Halliwell B; Jenner P
J Neural Transm (Vienna); 2002; 109(1):53-67. PubMed ID: 11793162
[TBL] [Abstract][Full Text] [Related]
22. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
23. L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.
Ando K; Inoue T; Itoh T
Pharmacol Biochem Behav; 2014 Dec; 127():62-9. PubMed ID: 25449794
[TBL] [Abstract][Full Text] [Related]
24. Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets.
Tayarani-Binazir KA; Jackson MJ; Rose S; Olanow CW; Jenner P
Mov Disord; 2010 Feb; 25(3):377-84. PubMed ID: 20108359
[TBL] [Abstract][Full Text] [Related]
25. The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.
Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
Eur J Pharmacol; 2015 Jan; 747():160-5. PubMed ID: 25499739
[TBL] [Abstract][Full Text] [Related]
26. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
Maratos EC; Jackson MJ; Pearce RK; Cannizzaro C; Jenner P
Exp Neurol; 2003 Jan; 179(1):90-102. PubMed ID: 12504871
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
Müller T
Clin Neuropharmacol; 2013; 36(3):84-91. PubMed ID: 23673910
[TBL] [Abstract][Full Text] [Related]
28. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP
J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558
[TBL] [Abstract][Full Text] [Related]
29. The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets.
Pearce RK; Smith LA; Jackson MJ; Banerji T; Scheel-Krüger J; Jenner P
Mov Disord; 2002 Sep; 17(5):877-86. PubMed ID: 12360536
[TBL] [Abstract][Full Text] [Related]
30. Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus.
Hamaue N; Ogata A; Terado M; Tsuchida S; Yabe I; Sasaki H; Hirafuji M; Togashi H; Aoki T
Brain Res; 2010 Jan; 1309():110-5. PubMed ID: 19879254
[TBL] [Abstract][Full Text] [Related]
31. Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
Hamadjida A; Nuara SG; Kwan C; Frouni I; Bédard D; Gourdon JC; Huot P
Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2157-2164. PubMed ID: 32621059
[TBL] [Abstract][Full Text] [Related]
32. Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.
Kuoppamäki M; Al-Barghouthy G; Jackson M; Smith L; Zeng BY; Quinn N; Jenner P
Mov Disord; 2002 Nov; 17(6):1312-7. PubMed ID: 12465074
[TBL] [Abstract][Full Text] [Related]
33. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Rioux L; Frohna PA; Joyce JN; Schneider JS
Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
[TBL] [Abstract][Full Text] [Related]
34. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.
Iravani MM; Tayarani-Binazir K; Chu WB; Jackson MJ; Jenner P
J Pharmacol Exp Ther; 2006 Dec; 319(3):1225-34. PubMed ID: 16959959
[TBL] [Abstract][Full Text] [Related]
35. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.
Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
Eur J Pharmacol; 2015 Nov; 766():25-30. PubMed ID: 26415982
[TBL] [Abstract][Full Text] [Related]
36. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
[TBL] [Abstract][Full Text] [Related]
37. Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or L-DOPA in MPTP-treated common marmosets.
Stockwell KA; Scheller DK; Smith LA; Rose S; Iravani MM; Jackson MJ; Jenner P
Exp Neurol; 2010 Jan; 221(1):79-85. PubMed ID: 19833125
[TBL] [Abstract][Full Text] [Related]
38. Cholinergic manipulation of motor disability and L-DOPA-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets.
Jackson MJ; Swart T; Pearce RK; Jenner P
J Neural Transm (Vienna); 2014 Feb; 121(2):163-9. PubMed ID: 23959162
[TBL] [Abstract][Full Text] [Related]
39. NB-355: a novel prodrug for L-DOPA with reduced risk for peak-dose dyskinesias in MPTP-treated squirrel monkeys.
Tye SJ; Rupniak NM; Naruse T; Miyaji M; Iversen SD
Clin Neuropharmacol; 1989 Oct; 12(5):393-403. PubMed ID: 2611764
[TBL] [Abstract][Full Text] [Related]
40. L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations.
Pearce RK; Heikkilä M; Lindén IB; Jenner P
Psychopharmacology (Berl); 2001 Aug; 156(4):402-9. PubMed ID: 11498717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]